Search

Ardelyx Inc

Slēgts

SektorsVeselības aprūpe

3.41 2.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.39

Max

3.43

Galvenie mērījumi

By Trading Economics

Ienākumi

21M

-17M

Pārdošana

26M

121M

EPS

-0.07

Peļņas marža

-13.833

Darbinieki

489

EBITDA

20M

-10M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+298.39% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-321M

909M

Iepriekšējā atvēršanas cena

1.31

Iepriekšējā slēgšanas cena

3.41

Ziņu noskaņojums

By Acuity

83%

17%

312 / 339 Rangs Healthcare

Ardelyx Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 18. sept. 19:36 UTC

Ardelyx Inc is experiencing upward movement, reaching an early afternoon peak, although it remains below its 20-day moving average and near the lower end of its one-month range.

2026. g. 16. sept. 20:10 UTC

Ardelyx Inc is seeing modest gains, increasing slightly since Tuesday's close, though it remains below its 20-day moving average after four consecutive declines.

2026. g. 15. sept. 20:07 UTC

Ardelyx Inc. shares are lower, extending a four-session decline amid negative sentiment from the NY Empire State Manufacturing Index's sharp drop.

2026. g. 14. sept. 20:13 UTC

Ardelyx Inc shares are higher in after-market trading, despite recent declines and no specific news driving the move. The U.S. dollar is strengthening.

2026. g. 10. sept. 20:01 UTC

Ardelyx Inc shares are lower during Thursday's session, breaking a trend of higher daily closes. No specific news was identified for the decline.

2026. g. 9. sept. 20:07 UTC

Ardelyx Inc shares are higher today, continuing an upward trend despite earlier pulling back from session highs. No specific news was identified for the movement.

2026. g. 8. sept. 20:01 UTC

Ardelyx Inc. shares are lower as biotechnology stocks face downward pressure. The asset pulled back after an early high during Tuesday's session.

2026. g. 2. sept. 20:08 UTC

Ardelyx Inc is rising on biotechnology sector strength during Wednesday's session, despite being below its 20-day moving average and near the one-month range low.

2026. g. 1. sept. 23:06 UTC

Ardelyx Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

2026. g. 31. aug. 20:07 UTC

Ardelyx Inc shares are lower amid broader market pressure from comments at the Jackson Hole Economic Symposium about persistent inflation and potential rate hikes.

2026. g. 28. aug. 20:08 UTC

Ardelyx Inc. shares are trading roughly flat amid no specific news. The stock remains near the lower end of its one-month trading range.

2026. g. 26. aug. 19:16 UTC

Ardelyx Inc. shares are higher Wednesday, recovering from an earlier dip amid notable volatility and broader market dynamics reflecting persistent inflationary pressures.

2026. g. 25. aug. 20:07 UTC

Ardelyx Inc shares are gaining amid broader market trends, supported by easing Treasury yields. The stock remains below its 20-day moving average.

2026. g. 21. aug. 19:16 UTC

Ardelyx Inc shares are higher today, continuing positive momentum since Thursday. No specific news was identified to explain the price movement.

2026. g. 20. aug. 20:01 UTC

News

Ardelyx Inc shares are lower amid a securities investigation into its revised IBSRELA revenue guidance, which was cut to $350-$370 million.

2026. g. 19. aug. 23:01 UTC

Ardelyx Inc. shares are higher in after-market trading, reflecting broader market gains. The stock remains below its 20-day moving average.

2026. g. 18. aug. 23:06 UTC

Ardelyx Inc. shares are roughly flat in after-market trading. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

2026. g. 17. aug. 19:26 UTC

News

Ardelyx shares are lower as Levi & Korsinsky investigates potential federal securities law violations amid reduced revenue guidance for IBSRELA.

2026. g. 14. aug. 23:56 UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

2026. g. 13. aug. 23:01 UTC

Ardelyx Inc. shares advanced modestly in after-market trading, though they remain significantly below the 20-day moving average and near the one-month range's lower end.

2026. g. 12. aug. 23:26 UTC

Ardelyx Inc. shares were trading roughly flat in after-market hours. The stock has declined significantly over the past month amid broader market weakness.

2026. g. 11. aug. 19:56 UTC

Ardelyx Inc's shares are lower today, reflecting a broader decline in the biotechnology sector. Investors monitor macroeconomic factors ahead of the Consumer Price Index report.

2026. g. 10. aug. 23:56 UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

2026. g. 7. aug. 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

2026. g. 6. aug. 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

2026. g. 3. aug. 19:16 UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

2026. g. 31. jūl. 19:16 UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

2026. g. 30. jūl. 23:51 UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

2026. g. 22. jūl. 19:31 UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

2026. g. 20. jūl. 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Salīdzinājums

Cenas izmaiņa

Ardelyx Inc Prognoze

Cenas mērķis

By TipRanks

298.39% augšup

Prognoze 12 mēnešiem

Vidējais 13.625 USD  298.39%

Augstākais 18 USD

Zemākais 9 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ardelyx Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

8

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

312 / 339 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.